Correlation Between Inhibikase Therapeutics and Anebulo Pharmaceuticals
Can any of the company-specific risk be diversified away by investing in both Inhibikase Therapeutics and Anebulo Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Inhibikase Therapeutics and Anebulo Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Inhibikase Therapeutics and Anebulo Pharmaceuticals, you can compare the effects of market volatilities on Inhibikase Therapeutics and Anebulo Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Inhibikase Therapeutics with a short position of Anebulo Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Inhibikase Therapeutics and Anebulo Pharmaceuticals.
Diversification Opportunities for Inhibikase Therapeutics and Anebulo Pharmaceuticals
-0.3 | Correlation Coefficient |
Very good diversification
The 3 months correlation between Inhibikase and Anebulo is -0.3. Overlapping area represents the amount of risk that can be diversified away by holding Inhibikase Therapeutics and Anebulo Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Anebulo Pharmaceuticals and Inhibikase Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Inhibikase Therapeutics are associated (or correlated) with Anebulo Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Anebulo Pharmaceuticals has no effect on the direction of Inhibikase Therapeutics i.e., Inhibikase Therapeutics and Anebulo Pharmaceuticals go up and down completely randomly.
Pair Corralation between Inhibikase Therapeutics and Anebulo Pharmaceuticals
Considering the 90-day investment horizon Inhibikase Therapeutics is expected to generate 0.83 times more return on investment than Anebulo Pharmaceuticals. However, Inhibikase Therapeutics is 1.21 times less risky than Anebulo Pharmaceuticals. It trades about 0.09 of its potential returns per unit of risk. Anebulo Pharmaceuticals is currently generating about 0.03 per unit of risk. If you would invest 134.00 in Inhibikase Therapeutics on November 2, 2024 and sell it today you would earn a total of 58.00 from holding Inhibikase Therapeutics or generate 43.28% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Insignificant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Inhibikase Therapeutics vs. Anebulo Pharmaceuticals
Performance |
| Timeline |
| Inhibikase Therapeutics |
| Anebulo Pharmaceuticals |
Inhibikase Therapeutics and Anebulo Pharmaceuticals Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Inhibikase Therapeutics and Anebulo Pharmaceuticals
The main advantage of trading using opposite Inhibikase Therapeutics and Anebulo Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Inhibikase Therapeutics position performs unexpectedly, Anebulo Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Anebulo Pharmaceuticals will offset losses from the drop in Anebulo Pharmaceuticals' long position.| Inhibikase Therapeutics vs. DiaMedica Therapeutics | Inhibikase Therapeutics vs. Milestone Pharmaceuticals | Inhibikase Therapeutics vs. Seres Therapeutics | Inhibikase Therapeutics vs. Oncolytics Biotech |
| Anebulo Pharmaceuticals vs. Adagene | Anebulo Pharmaceuticals vs. Acrivon Therapeutics, Common | Anebulo Pharmaceuticals vs. AnaptysBio | Anebulo Pharmaceuticals vs. Mineralys Therapeutics, Common |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Other Complementary Tools
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |